Psoriasis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | SFA Therapeutics, Palobiofarma, Sun Pharmaceutical, Dr. Reddy's, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Psoriasis pipeline constitutes key companies continuously working towards developing Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Psoriasis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market.

The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Psoriasis Pipeline Report: https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years.
• Psoriasis companies working in the treatment market are Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical, Dr. Reddy's, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, Arcutis Biotherapeutics, Jiangsu Hengrui Medicine, Akeso Biopharma, Dong-A ST Co., Ltd., Suzhou Zelgen Biopharmaceuticals, Nimbus Therapeutics, Meiji Pharma, Affibody, GC Cell Corporation, and others, are developing therapies for the Psoriasis treatment
• Emerging Psoriasis therapies in the different phases of clinical trials are- FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, ARQ-151, SHR 1314, AK101, DMB-3115, Jaktinib, NDI 034858, ME3183, ABY-035, CT 303, and others are expected to have a significant impact on the Psoriasis market in the coming years.
• In April 2023, The submission of a registration plan for a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis received a favourable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), according to a press release from Can-Fite BioPharma
• In May 2022, Deucravacitinib treatment for adult patients with moderate to severe plaque psoriasis has been shown to have lasting efficacy and a consistent safety profile, according to two-year data from the POETYK PSO long-term extension (LTE) experiment released by Bristol Myers Squibb. Clinical efficacy persisted for up to two years after starting deucravacitinib treatment, with response rates of 77.7% and 58.7% for static Physicians Global Assessment (sPGA) 0/1 (clean/almost clear skin) and psoriasis area and severity index (PASI) 75, respectively, at Week 60 in the LTE
• In April 2022, Amgen released the preliminary findings of a Phase 3 research comparing ABP 654 to STELARA® (ustekinumab) in treating adult patients with moderate to severe plaque psoriasis. The primary efficacy endpoint of the research was achieved, showing no clinically significant differences between ABP 654 and STELARA
• In March 2022, At the 2022 American Academy of Dermatology annual meeting, which was held in Boston, Massachusetts, Arcutis Biotherapeutics revealed fresh pooled findings from the DERMIS Phase III trials of roflumilast cream are available in four abstracts. Roflumilast is a very effective and selective PDE4 inhibitor that Arcutis is researching as a non-steroidal topical treatment for a variety of inflammatory skin conditions, including plaque psoriasis.

Psoriasis Overview
A chronic inflammatory skin condition known as psoriasis is brought on by a combination of immunological, environmental, and genetic factors. It has a variety of clinical symptoms. It is a dermatosis disease that is not communicable and affects nearly 2% of the global population. It can be seen as reoccurring red and scaly skin plaques that are clearly distinguishable from the healthy neighbouring skin.

Get a Free Sample PDF Report to know more about Psoriasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:
• FRTX-03: Fresh Tracks Therapeutics
• IMG-008: Inmagene
• SFA 002: SFA Therapeutics
• PBF-1650: Palobiofarma
• SCD-044: Sun Pharmaceutical Industries Limited
• PPC-06: Dr. Reddy's
• MP1032: MetrioPharm
• CT-P43: Celltrion
• ABP 654: Amgen
• Piclidenoson: Can-Fite Biopharma
• Topical roflumilast: Arcutis Biotherapeutics
• GSK2982772: GlaxoSmithKline

Psoriasis Route of Administration
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Psoriasis Molecule Type
Psoriasis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Psoriasis Pipeline Therapeutics Assessment
• Psoriasis Assessment by Product Type
• Psoriasis By Stage and Product Type
• Psoriasis Assessment by Route of Administration
• Psoriasis By Stage and Route of Administration
• Psoriasis Assessment by Molecule Type
• Psoriasis by Stage and Molecule Type

DelveInsight's Psoriasis Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Psoriasis product details are provided in the report. Download the Psoriasis pipeline report to learn more about the emerging Psoriasis therapies at:
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Psoriasis Therapeutics Market include:
Key companies developing therapies for Psoriasis are - Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others.

Psoriasis Pipeline Analysis:
The Psoriasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
• Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Psoriasis drugs and therapies-
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Psoriasis Pipeline Market Drivers
• Increasing prevalence of Psoriasis across the globe, increasing combinational therapies• An increase witnessed in Biological therapy approvals for Psoriasis are some of the important factors that are fueling the Psoriasis Market.

Psoriasis Pipeline Market Barriers
• However, side effects associated with the treatment, high-cost treatment and Unfavourable Reimbursement policies and other factors are creating obstacles in the Psoriasis Market growth.

Scope of Psoriasis Pipeline Drug Insight
• Coverage: Global
• Key Psoriasis Companies: Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical, Dr. Reddy's, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, Arcutis Biotherapeutics, Jiangsu Hengrui Medicine, Akeso Biopharma, Dong-A ST Co., Ltd., Suzhou Zelgen Biopharmaceuticals, Nimbus Therapeutics, Meiji Pharma, Affibody, GC Cell Corporation, and others
• Key Psoriasis Therapies: FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, ARQ-151, SHR 1314, AK101, DMB-3115, Jaktinib, NDI 034858, ME3183, ABY-035, CT 303, and others
• Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
• Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers

Request for Sample PDF Report for Psoriasis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Psoriasis Report Introduction
2. Psoriasis Executive Summary
3. Psoriasis Overview
4. Psoriasis- Analytical Perspective In-depth Commercial Assessment
5. Psoriasis Pipeline Therapeutics
6. Psoriasis Late Stage Products (Phase II/III)
7. Psoriasis Mid Stage Products (Phase II)
8. Psoriasis Early Stage Products (Phase I)
9. Psoriasis Preclinical Stage Products
10. Psoriasis Therapeutics Assessment
11. Psoriasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Psoriasis Key Companies
14. Psoriasis Key Products
15. Psoriasis Unmet Needs
16 . Psoriasis Market Drivers and Barriers
17. Psoriasis Future Perspectives and Conclusion
18. Psoriasis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Psoriasis Market https://www.delveinsight.com/report-store/psoriasis-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Psoriasis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.